Skip to content

The Vitamin K2 and D3 Intervention Trial in Children and Adolescents With the Low-energy Fractures

Rationale and Design of the Vitamin K2 and Vitamin D3 Intervention Trial in Children and Adolescents With the Low-energy Bone Fractures

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03871322
Enrollment
90
Registered
2019-03-12
Start date
2019-07-01
Completion date
2023-01-20
Last updated
2021-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deficiency of Vitamin K2, Fracture Healing, Vitamin D3

Keywords

vitamin D, vitamin K2, low-energy fractures, fracture healing, children

Brief summary

a prospective, three- month, randomized, double-blind, placebo-controlled, intervention trial (RDBPC), investigating the effect of vitamin K2 (menaquinone-7) and vitamin D3 on the healing process of low-energy bone fractures in children and adolescents

Detailed description

At the admission of patients to the orthopedic outpatient clinic, presence of low- energy fractures will be established based on the anamnesis, physical examination and radiological evaluation. Tests to obtain the baseline blood levels of vitamin D3 will be performed, and only children with vitamin D3 levels lower than 30ng/ml in the blood will be included in the study. The selected population will then be randomly assigned by an independent investigator to the three study groups, receiving daily for three months identical- looking soft gel capsules (1 capsule/patient/day) containing supplements of vitamin D3 2,000 IU, 90 mcg of vitamin K2 as menaquinone-7 combined with 2,000 IU D3, and olive oil-containing placebo capsules respectively. During the 3-month follow-up visits to the outpatient orthopedic clinic, the pediatric orthopedist will examine the patient, evaluate the X-ray, and determine the progress in bone union and the range of joint motion. The patients will visit the clinic on weeks 1,2,4,6,8, and 12. The compliance taking the supplements will be assessed by registering a pill count returned by a patient during the scheduled visit. The blood samples will be collected upon admission to the study, day 0, and after the 3-month regimen. The blood samples will be collected for evaluation of bone turnover markers and the status of vitamin K and vitamin D3. The primary evaluation endpoints will include: the dynamics of fracture healing, changes in levels of osteocalcin, and vitamin K and vitamin D3 levels against the placebo group. The bone fracture healing milestones will be based on bone union defined as the absence of pain and the presence of bridging callus in three of the four cortices seen on the front rear projection and lateral radiographic views of the bone. Delayed union is defined as incomplete consolidation at 90 Days

Interventions

DIETARY_SUPPLEMENTVitamin D and K2 supplementation

if supplementation of vitamin D and K2 changes the time to fracture healing

DIETARY_SUPPLEMENTVitamin D supplementation

if supplementation of vitamin D alone changes the time to fracture healing

DIETARY_SUPPLEMENTPlacebo

Placebo control group

Sponsors

Lomza State University of Applied Sciences
CollaboratorUNKNOWN
International Science & Health Foundation
CollaboratorUNKNOWN
American Medical Holdings Inc
CollaboratorUNKNOWN
Medical University of Bialystok
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

double-blind, placebo, same looking capsules

Intervention model description

a prospective, three- month, randomized, double-blind, placebo-controlled, intervention trial (RDBPC),

Eligibility

Sex/Gender
ALL
Age
3 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Age \< 18 years * Presence of low-energy fracture * Vitamin D serum level \<30ng/ml

Exclusion criteria

* Age \> 18 years * Lack of low-energy bone fracture * Oral anticoagulants treatments, which interfere with vitamin K cycle * Current supplementation with vitamin vitamins K2 or vitamin D3 * Osteogenesis imperfecta and other bone diseases * Vitamin D concentration \> 30ng/ml

Design outcomes

Primary

MeasureTime frameDescription
time to bone union3 monthsThe bone fracture healing milestones will be based on bone union defined as the absence of pain and the presence of bridging callus in three of the four cortices seen on the AnteroPosteral and lateral radiographs

Secondary

MeasureTime frameDescription
Vitamin D concentration changes3 monthschanges in vitamin D serum concentration
Vitamin K2 concentration changes3 monthschanges in vitamin K2 serum concentration
Changes in bone markers concentration3 monthsChanges in bone-specific alkaline phosphatase (BALP), N-terminal telopeptide (NTX)

Countries

Poland

Contacts

Primary ContactMichał Karpiński, MD
gufkarp@gmail.com692224714

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026